Targeted Agents Plus CHOP Compared with CHOP As the First-Line Treatment for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma (GUIDANCE-03): an Open-Label, Multicentre Phase 2 Clinical Trial
LANCET REGIONAL HEALTH-WESTERN PACIFIC（2024）
Key words
Peripheral T-cell lymphoma,Decitabine,Azacytidine,Tucidinostat,Lenalidomide,CHOP,Complete response rate,Prognosis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined